Market Place
Sourcing Support
Tectonic Closes AVROBIO Merger And Raises $130.7M In Concurrent Placement
20 Jun 2024 //
BUSINESSWIRE
AVROBIO and Tectonic Therapeutic Announce Merger
30 Jan 2024 //
BUSINESSWIRE
Avrobio stops programs, halves head count and searches for exit
12 Jul 2023 //
FIERCE BIOTECH
AVROBIO to Explore Strategic Alternatives
12 Jul 2023 //
BUSINESSWIRE
Novartis Buys Avrobio Gene Therapy for $88 Million
31 May 2023 //
CONTRACT PHARMA
Novartis to buy Avrobio gene therapy for $88M, ending M&A rumor
23 May 2023 //
FIERCE BIOTECH
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5M
22 May 2023 //
BUSINESSWIRE
AVROBIO Announces Data from Phase 1/2 Clinical Trial of Cystinosis at ASGCT
18 May 2023 //
BUSINESSWIRE
AVROBIO Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Avrobio Reports Fourth Quarter and Fiscal Year 2022 Financial Results
23 Mar 2023 //
BUSINESSWIRE
AVROBIO to Present Data from Lysosomal Disorder Gene Therapy Pipeline
09 Feb 2023 //
BUSINESSWIRE
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Jan 2023 //
BUSINESSWIRE
AVROBIO Announces Positive Clinical Data and Outlines Clinical Development Plan
07 Dec 2022 //
BUSINESSWIRE
Avrobio touts early clinical data and plans new gene therapy trial in 2023
07 Dec 2022 //
ENDPTS
Avrobio hopes to get investors back on gene therapy bandwagon
06 Dec 2022 //
FIERCEBIOTECH
AVROBIO to Share Comprehensive Gaucher Disease Program Update
17 Nov 2022 //
BUSINESSWIRE
AVROBIO Announces Completion of Dosing in Gene Therapy Trial for Cystinosis
25 Oct 2022 //
BUSINESSWIRE
AVROBIO Granted ILAP Designation from U.K. MHRA
19 Oct 2022 //
BUSINESSWIRE
Avrobio CEO shares outlook on cell and gene landscape
30 Sep 2022 //
FIERCEBIOTECH
Avrobio receives FDA rare pediatric disease status for cystinosis therapy
21 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
AVROBIO Announces nMPS-II to Initiate Phase 1/2 Gene Therapy Trial
14 Sep 2022 //
BUSINESSWIRE
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Sep 2022 //
BUSINESSWIRE
AVROBIO to Participate in Four Upcoming Investor Conferences in September
31 Aug 2022 //
BUSINESSWIRE
AVROBIO Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
AVROBIO Receives ODD from FDA for AVR-RD-05 in MPSII or Hunter Syndrome
13 Jul 2022 //
BUSINESSWIRE
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease
18 May 2022 //
BUSINESSWIRE
AVROBIO Reports Positive Data From PI/II Trial of Gene Therapy for Cystinosis
17 May 2022 //
BUSINESSWIRE
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
16 May 2022 //
BUSINESSWIRE
AVROBIO Reports First Quarter 2022 Financial Results
10 May 2022 //
BUSINESSWIRE
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 May 2022 //
BUSINESSWIRE
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 Apr 2022 //
BUSINESSWIRE
AVROBIO Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
BUSINESSWIRE
AVROBIO Reports Q4 and FY 2021 Financial Results
16 Mar 2022 //
BUSINESSWIRE
Avrobio gene therapy shows signs of durability in rare disorder
10 Feb 2022 //
BENZINGA
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Feb 2022 //
BUSINESSWIRE
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
01 Feb 2022 //
BUSINESSWIRE
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis
27 Jan 2022 //
BUSINESSWIRE
Avrobio ditches Fabry, eyes 2023 trials for other gene therapies
05 Jan 2022 //
FIERCEBIOTECH
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial
24 Nov 2021 //
BIOSPACE
AVROBIO Receives RPDD from FDA for AVR-RD-05
03 Nov 2021 //
BUSINESSWIRE
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies
19 Oct 2021 //
BUSINESSWIRE
Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting
19 Oct 2021 //
BUSINESSWIRE
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Oct 2021 //
BUSINESSWIRE
AVROBIO to Present at Two Upcoming Investor Conferences in August
02 Aug 2021 //
BUSINESS WIRE
AVROBIO to Present at the JMP Securities Life Sciences Conference
10 Jun 2021 //
BUSINESSWIRE
Avrobio revises regulatory plan for Fabry gene therapy
04 May 2021 //
FIRSTWORDPHARMA
Avrobio plans head-to-head Fabrazyme trial after FDA changes path to market
04 May 2021 //
FIERCEBIOTECH
Avrobio retools Fabry gene therapy plans after competing drug`s full approval
03 May 2021 //
ENDPTS
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01
03 May 2021 //
BUSINESSWIRE
Avrobio is using `pods` to create gene therapies, and it believes
15 Apr 2021 //
ENDPTS
AVROBIO Reports Q4 and FY 2020 Financial Results and Provides Business Update
18 Mar 2021 //
BUSINESSWIRE
AVROBIO Receives Orphan Drug Designation from the European for AVR?RD?04
01 Mar 2021 //
BUSINESSWIRE
AVROBIO Receives Orphan Drug Designation from the European for AVR?RD?04
25 Feb 2021 //
BUSINESSWIRE
AVROBIO reports 100% kidney substrate reduction in Fabry disease trial
09 Feb 2021 //
CLINICALTRIALSARENA
AVROBIO Announces Multiple Clinical Data Presentations, Posters Events at 17th
01 Feb 2021 //
BUSINESSWIRE
AVROBIO Announces Closing of Underwritten Public Offering
24 Nov 2020 //
BUSINESSWIRE
Avrobio posts data on first Gaucher gene therapy patient
17 Nov 2020 //
FIERCE BIOTECH
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well
17 Nov 2020 //
BIOSPACE
AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well
17 Nov 2020 //
BUSINESSWIRE
Avrobio posts data on first Gaucher gene therapy patient
16 Nov 2020 //
FIERCE BIOTECH
